PillRx only · Injection · Intramuscular
Orphenadrine Citrate
Orphenadrine Citrate
2 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US2 NDCs
2 active makers
2 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$7.074
Latest avg · Jul 22, 2026
+0%
Since Feb 18, 2026
2
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
3.4K
Rx · 2026 Q1
7.9K
Units dispensed
+101%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it2 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Actavis Pharma, Inc. | unknown | 1 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | unknown | 1 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.